Illumina debuts its multi-gene test for cancer in Europe
pharmaphorum
MARCH 15, 2022
Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. The company is preparing to file for FDA approval of TruSight Oncology in the US later this year.
52 
Let's personalize your content